Anika Therapeutics, Inc.
ANIK- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0000898437
No open-market purchases or sales by Anika Therapeutics, Inc. insiders were filed in the last 90 days; 133 institutions reported holding it in 13F filings for Q2 2026, worth $179.0M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $179.5M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +6 vs. previous quarter
- 133
- 13F valueReported value at the end of Q2 2026
- $179.0M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $112.8M
- −5.9% year over year
- Net income, FY2025
- -$10.9M
- No comparable prior period
- Free cash flow, FY2025
- $4.36M
- No comparable prior period
- Revenue, Q3 FY2026
- $30.6M
- +10.0% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $10.9M (9.6% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 323.5K
- Shares sold short
- Change
- −42.2K
- −11.5% vs. previous
- Days to cover
- 3.13
- At average daily volume
Superinvestors holding ANIK, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ANIK at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Anika Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 5, 2026 (view filing)4:30 PM ET | Aug 3-4 | 2 days | Fishetti Gary PDirector | PPurchase | +2.00K | $20.53 | +$41.1K | +3.8%54.0K after | 2 lots |
| May 4, 2026 (view filing) | May 1 | 3 days | Henneman John B IIIDirector | PPurchase | +5.00K | $14.66 | +$73.3K | +10.0%54.9K after | |
| Apr 30, 2026 (view filing) | Apr 30 | Same day | Griffin Stephen D.President and CEO | PPurchase | +12.2K | $12.29 | +$149.9K | +50.9%36.2K after | |
| May 12, 2022 (view filing) | May 11 | 1 day | Colleran DavidEVP, General Counsel, Corp Sec | PPurchase | +1.50K | $21.37 | +$32.1K | +17.9%9.87K after | |
| Mar 16, 2022 (view filing) | Mar 14 | 2 days | Colleran DavidEVP, General Counsel, Corp Sec | PPurchase | +1.50K | $26.65 | +$40.0K | +21.8%8.37K after | |
| Mar 15, 2022 (view filing) | Mar 11 | 4 days | Thompson Jeffery SDirector | PPurchase | +2.00K | $24.66 | +$49.3K | +13.2%17.1K after | |
| Mar 14, 2022 (view filing) | Mar 11 | 3 days | Blanchard Cheryl RPresident, CEO, Director | PPurchase | +8.10K | $25.57 | +$207.1K | +15.6%60.0K after | 2 lots |
| Mar 14, 2022 (view filing) | Mar 11 | 3 days | Levitz Michael LEVP, CFO, Treasurer | PPurchase | +4.00K | $24.62 | +$98.5K | +33.5%15.9K after | |
| Aug 13, 2021 (view filing) | Aug 11-12 | 2 days | Levitz Michael LEVP, CFO, Treasurer | PPurchase | +3.63K | $40.21 | +$145.8K | +94.0%7.49K after | 2 lots |
Top 10 13F holders, Q2 2026
See all 133 holdersThe largest institutional positions in Anika Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 1,449,671 | $21.2M | 0.00% | −145,222−9.1% | Reduced |
| Caligan Partners LP | 1,435,130 | $21.0M | 1.01% | 00.0% | Unchanged |
| Morgan Stanley | 614,320 | $8.99M | 0.00% | −257,746−29.6% | Reduced |
| Acadian Asset Management LLC | 606,544 | $8.87M | 0.01% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 572,113 | $8.37M | 0.00% | −33,664−5.6% | Reduced |
| AQR Capital Management LLC | 559,846 | $8.19M | 0.00% | +287,577+105.6% | Added |
| Boothbay Fund Management, LLC | 529,640 | $7.75M | 0.15% | +1370.0% | Added |
| Renaissance Technologies LLC | 481,417 | $7.04M | 0.01% | −20,800−4.1% | Reduced |
| Dimensional Fund Advisors LP | 451,095 | $6.60M | 0.00% | −7,752−1.7% | Reduced |
| Capital Management Corp | 448,474 | $6.56M | 0.98% | +753+0.2% | Added |
Holders of 5% or more of ANIK
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Anika Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Caligan Partners LP | 13D/A | 9.95%1.44M shares | 0.00 ppfrom 9.95% | Aug 17, 20236 filings | Jan 27, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.80%963.1K shares | −3.80 ppfrom 10.60% | Oct 23, 20244 filings | Apr 17, 2025 | SEC |
Politician trades
All politician trades in ANIK1 member of Congress reported 8 trades in Anika Therapeutics, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Aug 26, 2021 |  Tom Malinowski House · NJ | Buy | $1K-$15K |
| Aug 26, 2021 | Tom Malinowski House · NJ | Buy | $1K-$15K |
| Aug 26, 2021 | Tom Malinowski House · NJ | Sell (partial) | $1K-$15K |
| Aug 26, 2021 | Tom Malinowski House · NJ | Sell (partial) | $1K-$15K |
| Aug 26, 2021 | Tom Malinowski House · NJ | Sell (partial) | $1K-$15K |
House · NJ · Aug 26, 2021
Buy$1K-$15K
House · NJ · Aug 26, 2021
Buy$1K-$15K
House · NJ · Aug 26, 2021
Sell (partial)$1K-$15K
House · NJ · Aug 26, 2021
Sell (partial)$1K-$15K
House · NJ · Aug 26, 2021
Sell (partial)$1K-$15K